| Literature DB >> 33994944 |
Sunil Q Mehta1,2, Supriya Behl3, Patrick L Day4, Adriana M Delgado3, Nicholas B Larson5, Lindsay R Stromback3, Andrea R Huebner1,2, Timothy R DeGrado6, Jessica M Davis7, Paul J Jannetto4, Flora Howie1,2, Mukesh K Pandey6.
Abstract
Metal ion dyshomeostasis and disparate levels of biometals like zinc (Zn), copper (Cu), and selenium (Se) have been implicated as a potential causative factor for Autism Spectrum Disorder (ASD). In this study, we have enrolled 129 children (aged 2-4 years) in North America, of which 64 children had a diagnosis of ASD and 65 were controls. Hair, nail, and blood samples were collected and quantitatively analyzed for Zn, Cu and Se using inductively coupled plasma mass spectrometry (ICP-MS). Of the analyzed biometals, serum Se (116.83 ± 14.84 mcg/mL) was found to be significantly lower in male ASD cases compared to male healthy controls (128.21 ± 9.11 mcg/mL; p < 0.005). A similar trend was found for nail Se levels in ASD (1.01 ± 0.15 mcg/mL) versus that of controls (1.11 ± 0.17 mcg/mL) with a p-value of 0.0132 using a stratified Wilcoxon rank sum testing. The level of Se in ASD cohort was co-analyzed for psychometric correlation and found a negative correlation between total ADOS score and serum Se levels. However, we did not observe any significant difference in Zn, Cu, and Zn/Cu ratio in ASD cases versus controls in this cohort of North American children. Further studies are recommended to better understand the biology of the relationship between Se and ASD status.Entities:
Keywords: Cu; Se; Zn; autism spectrum disorder; biometals
Year: 2021 PMID: 33994944 PMCID: PMC8116541 DOI: 10.3389/fnmol.2021.665686
Source DB: PubMed Journal: Front Mol Neurosci ISSN: 1662-5099 Impact factor: 5.639
25 selenoproteins and characteristics.
| Selenoprotein | Gene | Age at peak transcription | Autism-related gene? |
|
| |||
| Cytosolic GPx (cGPx, GPx-1) |
| 8 years | Yes |
| Gastrointestinal GPx (GI-GPx, GPx-2) |
| Unknown | |
| Plasma GPx (pGPx, GPx-3) |
| 37 pcw | |
| Phospholipid hydroperoxide GPx (PHGPx, GPx-4) |
| 4 years | |
| Sperm nuclei GPx (snGPx) |
| ||
| GPx-6 |
| Unknown | |
|
| |||
| Thioredoxin reductase 1 (TrxR1) |
| Unknown | |
| Thioredoxin reductase 2 (TrxR2, SelZf1, SelZf2) |
| Unknown | |
| Thioredoxin reductase 3 (TrxR3, TGR) |
| Unknown | |
|
| |||
| Type 1 deiodinase (DIO1, IOD1, D1) |
| Unknown | |
| Type 2 deiodinase (DIO2, IOD2, D2) |
| 4 months | |
| Type 3 deiodinase (DIO3, IOD3, D3) |
| 12 pcw | |
| Selenophosphate synthetase (SPS2) |
| Unknown | |
| Selenoprotein S (SelS, VIMP) |
| Unknown | |
| Selenoprotein P (SEPP1, SelP) |
| 8, 21 years | |
| Selenoprotein 15 kDa (Sel15) | SEP15 | 4 years | |
| Selenoprotein N (SelN) |
| Unknown | |
| Selenoprotein X (SelX or SelR) |
| 8 years | |
| Selenoprotein W (SelW) |
| 4–8 years | |
| Selenoprotein T (SelT) | SEPT1 | Unknown | |
| Selenoprotein H | SELH | 4 years | |
| Selenoprotein I | SELI | Unknown | |
| Selenoprotein K | SELK | 3–4 years | |
| Selenoprotein M | SELM | 8 years | |
| Selenoprotein O | SELO | Unknown | |
| Selenoprotein V | SELV | Unknown | |
Characteristics of case and control study subjects.
| ASD ( | Control ( | Total ( | ||
|
| 0.022 | |||
| Median (SD) | 38.5 (7.73) | 36 (6.62) | 36 (7.29) | |
|
| <0.001 | |||
| Female | 10(15.6%) | 30(46.2%) | 40(31.0%) | |
| Male | 54(84.4%) | 35(53.8%) | 89(69.0%) | |
|
| 0.153 | |||
| Asian | 3(4.7%) | 1(1.5%) | 4(3.1%) | |
| Black or African American | 4(6.2%) | 0(0.0%) | 4(3.1%) | |
| More than one race | 0(0.0%) | 1(1.5%) | 1(0.8%) | |
| Unknown/Not reported | 10(15.6%) | 14(21.5%) | 24(18.6%) | |
| White | 47(73.4%) | 49(75.4%) | 96(74.4%) | |
|
| 0.103 | |||
| Hispanic or Latino | 8(12.5%) | 2(3.1%) | 10(7.8%) | |
| NOT Hispanic or Latino | 45(70.3%) | 46(71.9%) | 91(71.1%) | |
| Unknown/Not reported | 11(17.2%) | 16(25.0%) | 27(21.1%) | |
|
| <0.001 | |||
| Median (SD) | 96.75 (6.13) | 94 (5.71) | 95.4 (6.24) | |
|
| <0.001 | |||
| Median (SD) | 15.7 (3.01) | 14.1 (1.93) | 14.6 (2.70) | |
|
| 0.129 | |||
| Median (SD) | 16.69 (2.01) | 16.35 (1.30) | 16.5 (1.72) |
Median Cu, Zn, and Se levels for cases and controls, stratified by sex.
| ASD ( | Control ( | ||
|
| 1.37 (0.26) | 1.32 (0.19) | 0.75642 |
| Female | 1.29 (0.20) | 1.23 (0.08) | 0.85867 |
| Male | 1.39 (0.27) | 1.38 (0.21) | 0.99245 |
|
| 0.75 (0.16) | 0.81 (0.30) | 0.57792 |
| Female | 0.74 (0.15) | 0.69 (0.08) | 0.4239 |
| Male | 0.75 (0.16) | 0.88 (0.35) | 0.23092 |
|
| 116.67 (14.75) | 121.37 (13.69) | 0.07166 |
| Female | 115.96 (15.16) | 109.41 (12.29) | 0.32838 |
| Male | 116.83 (14.84) | 128.21 (9.11) |
|
FIGURE 1ROC curve of serum Se values for cases vs. controls among males, along with confidence interval regions for sensitivity over a grid of specificities (indicated in shaded blue region). An estimate of the AUC and its 95% confidence interval (in parentheses) is also provided.
Median Se levels between cases and controls, stratified by sex.
| ASD | Control | ||
|
| 0.58 (0.13) | 0.66 (0.20) | |
| Female | 0.59( | 0.68 (0.26) | – |
| Male | 0.58 (0.14) | 0.63 (0.11) | 0.2992 |
|
| 1.00 (0.14) | 1.11 (0.16) | |
| Female | 0.96( | 1.11 (0.15) | – |
| Male | 1.01 (0.15) | 1.11 (0.17) |
|
Tau rank correlations between various psychometric test scores and serum Se levels, in all patients and males only.
| Test | Value | Sample size (All) | τ (All) | Sample size (Males) | τ (Males) | ||
| Vineland | Communication | 30 | 0.135 | 0.3 | 25 | 0.149 | 0.303 |
| Vineland | Daily living skills | 31 | 0.162 | 0.207 | 26 | 0.072 | 0.611 |
| Vineland | Socialization | 28 | 0.145 | 0.285 | 23 | 0.116 | 0.443 |
| Vineland | Motor skills | 28 | 0.032 | 0.812 | 24 | −0.011 | 0.941 |
| ADOS | Restricted repetitive behavior | 39 | −0.216 | 0.058 | 30 | −0.35 | 0.008 |
| ADOS | Social affect | 39 | 0.016 | 0.892 | 30 | −0.017 | 0.899 |
| ADOS | Total score | 41 | −0.26 | 0.02 | 32 | −0.404 | 0.002 |
| Preschool language scale | Auditory comprehension | 30 | 0.118 | 0.369 | 22 | 0.102 | 0.514 |
| Preschool language scale | Expressive communication | 30 | 0.111 | 0.399 | 22 | 0.185 | 0.242 |
FIGURE 2Scatterplots of ADOS Results and serum Se levels along with fitted linear trends, stratified by sex.
Kendall’s Tau rank correlation between serum Se levels and BMI, overall and stratified by sex and case-status.
| Sex | Case status | τ | |
| All | All | 0.134 | 0.091 |
| Male | All | 0.166 | 0.07 |
| Female | All | −0.098 | 0.601 |
| All | ASD | 0.165 | 0.084 |
| Male | ASD | 0.24 | 0.025 |
| Female | ASD | −0.156 | 0.601 |
| All | Control | 0.221 | 0.16 |
| Male | Control | 0.231 | 0.279 |
| Female | Control | −0.143 | 0.72 |
FIGURE 3Scatterplots of BMI and serum Se levels along with fitted linear trends, stratified by sex.